Cover Image
市場調查報告書

足癬(香港腳)的開發中產品分析

Tinea pedis (Athlete Foot) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 213129
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
足癬(香港腳)的開發中產品分析 Tinea pedis (Athlete Foot) - Pipeline Review, H1 2017
出版日期: 2017年06月27日 內容資訊: 英文 44 Pages
簡介

足癬(香港腳)是腳部最常見的感染症,是由被稱為白癬菌的真菌所引起。主要症狀有皮膚乾燥化、剝離、腳部發臭、腳掌產生很小又癢的水疱等。主要治療法有抗真菌藥。

本報告提供全球各國治療足癬(香港腳)用的開發中產品開發情形相關分析,提供產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

足癬(香港腳)概要

治療藥的開發

  • 足癬用開發中產品:概要
  • 足癬用開發中產品:比較分析

各企業開發中的足癬治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

足癬治療藥:開發中的產品一覽(各企業)

足癬治療藥的開發企業

  • Actavis plc
  • Helix BioMedix, Inc.
  • Anacor Pharmaceuticals, Inc.
  • Viamet Pharmaceuticals, Inc.

足癬:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 分子類別

藥物簡介

  • albaconazole
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • VT-1161
  • AN-2718
  • HB-1275
  • 檸檬酸二氫燃料銀

足癬治療藥:開發中產品的最新趨勢

足癬治療藥:暫停開發的產品

足癬相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全3件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9446IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tinea pedis (Athlete Foot) - Pipeline Review, H1 2017, provides an overview of the Tinea pedis (Athlete Foot) (Infectious Disease) pipeline landscape.

Athlete's foot, also known as tinea pedis, is a common foot infection caused by fungi called dermatophytes. Symptoms include dry flaking skin on the soles of the feet, unpleasant foot odour and small itchy bubbles or blisters on the soles of the feet. Treatment includes antifungal medicines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tinea pedis (Athlete Foot) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Tinea pedis (Athlete Foot) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tinea pedis (Athlete Foot) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tinea pedis (Athlete Foot) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical, Discovery and Unknown stages are 1, 5, 2, 1 and 1 respectively.

Tinea pedis (Athlete Foot) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tinea pedis (Athlete Foot) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tinea pedis (Athlete Foot) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tinea pedis (Athlete Foot) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tinea pedis (Athlete Foot) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tinea pedis (Athlete Foot) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tinea pedis (Athlete Foot) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tinea pedis (Athlete Foot) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tinea pedis (Athlete Foot) - Overview
    • Tinea pedis (Athlete Foot) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Tinea pedis (Athlete Foot) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Tinea pedis (Athlete Foot) - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc
    • Biolab Farmaceutica Ltda
    • Blueberry Therapeutics Ltd
    • Dermala Inc
    • Helix BioMedix Inc
    • Novan Inc
    • Sol-Gel Technologies Ltd
    • Viamet Pharmaceuticals Inc
  • Tinea pedis (Athlete Foot) - Drug Profiles
    • AS-2077715 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dapaconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Athlete's Foot - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-1275 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nitric oxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-208 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • terbinafine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • terbinafine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VT-1161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tinea pedis (Athlete Foot) - Dormant Projects
  • Tinea pedis (Athlete Foot) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 12, 2017: Novan Reports Positive Topline Results with SB208 in Phase 2 Trial
      • Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program
      • Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting
      • Jul 09, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis
      • Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Tinea pedis (Athlete Foot), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Tinea pedis (Athlete Foot) - Pipeline by Astellas Pharma Inc, H1 2017
  • Tinea pedis (Athlete Foot) - Pipeline by Biolab Farmaceutica Ltda, H1 2017
  • Tinea pedis (Athlete Foot) - Pipeline by Blueberry Therapeutics Ltd, H1 2017
  • Tinea pedis (Athlete Foot) - Pipeline by Dermala Inc, H1 2017
  • Tinea pedis (Athlete Foot) - Pipeline by Helix BioMedix Inc, H1 2017
  • Tinea pedis (Athlete Foot) - Pipeline by Novan Inc, H1 2017
  • Tinea pedis (Athlete Foot) - Pipeline by Sol-Gel Technologies Ltd, H1 2017
  • Tinea pedis (Athlete Foot) - Pipeline by Viamet Pharmaceuticals Inc, H1 2017
  • Tinea pedis (Athlete Foot) - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Tinea pedis (Athlete Foot), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top